Kiniksa Pharmaceuticals

Historical price data

Founded in 2015 and publicly traded on NASDAQ, Kiniksa Pharmaceuticals is dedicated to advancing transformative therapies, with a core focus on cardiovascular diseases. Its key achievement is the 2021 FDA approval and commercial launch of ARCALYST for recurrent pericarditis, providing a critical treatment for a serious inflammatory heart condition. The company's strategy involves leveraging validated immune-modulating pathways, pursuing multiple indications for its assets, and forming strategic collaborations to expand its global reach and pipeline potential.

Kiniksa's strategy focuses on targeted immune modulation, developing and commercializing therapies that act on specific, validated immunologic pathways (e.g., IL-1, GM-CSFRα, CD40) to address serious diseases with high unmet need.

14 drugs in pipeline, 3 in Phase 3

Total raised: $300M

In recurrent pericarditis, ARCALYST competes against generic standard-of-care (NSAIDs, colchicine). Its key advantage is being the only FDA-approved therapy. In broader autoimmune indications, pipeline candidates face intense competition from large pharma; differentiation will be critical.